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Abstract
Introduction: Anti-TNF drugs have proven to be effective against spondyloarthritis (SpA), although 30% of patients
fail to respond or experience adverse events leading to treatment discontinuation. In rheumatoid arthritis, the
presence of anti-drug antibodies (ADA) against the first TNF inhibitor influences the outcome after switching. Our
aim was to assess whether the response to a second anti-TNF drug is related to the previous development of ADA
to the first anti-TNF drug SpA patients.
Methods: Forty-two SpA patients began a second anti-TNF drug after failing to respond to the first anti-TNF
therapy. Clinical activity was assessed by the Ankylosing Spondylitis Disease Activity Score (ASDAS) at baseline (at
the beginning of the first and second anti-TNF therapy) and at 6 months after switching. The drug and ADA levels
were measured by ELISA before each administration.
Results: All patients were treated with anti-TNF drugs and mainly due to inefficacy were switched to a second
anti-TNF drug. Eleven of 42 (26.2%) developed ADA during the first biologic treatment. At baseline, no differences
in ASDAS were found in patients with or without ADA to the first anti-TNF drug (3.52 ± 1.03 without ADA vs. 3.14
± 0.95 with ADA, p = 0.399) and to the second anti-TNF drug (3.36 ± 0.94 without ADA vs. 3.09 ± 0.91 with ADA, p
= 0.466). At 6 months after switching, patients with previous ADA had lower disease activity (1.62 ± 0.93 with ADA
vs. 2.79 ± 1.01 without ADA, p = 0.002) and most patients without ADA had high disease activity state by the
ASDAS (25 out of 31 (80.6%) without ADA vs. 3 out of 11 (27.3%) with ADA, p = 0.002).
Conclusions: In SpA the failure to respond to the first anti-TNF drug due to the presence of ADA predicts a better
clinical response to a second anti-TNF drug.
Introduction
Spondyloarthritis (SpA) describes a group of diseases
including ankylosing spondylitis (AS), psoriatic SpA, SpA
related to inflammatory bowel disease (IBD), reactive
arthritis, a subgroup of juvenile idiopathic arthritis and
nonradiographic axial spondyloarthritis [1]. Several
studies have demonstrated the efficacy of biological
agents, such as anti-TNFa drugs, for treating SpA
patients [2-9].
The available anti-TNF drugs differ in chemical struc-
ture, half-life, route of application and capacity to
induce immunogenicity, and they also have somewhat
different mechanisms of action [10,11]. Although the
efficacy of anti-TNF drugs against SpA has been shown
in large, randomised clinical trials [6,12-16], it is known
that some patients fail to respond to treatment or
experience adverse events necessitating treatment
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discontinuation [11,17]. Part of this treatment failure
can be explained by the development of anti-drug anti-
bodies (ADA) [17-20].
To date, only two studies have been published that
correlate the clinical response and immunogenicity to
anti-TNF drugs in rheumatoid arthritis (RA) patients
who switched to a second anti-TNF drug [21,22]. In
these studies, RA patients with ADA against the first
anti-TNF drug have been shown to have a better clinical
response after switching to a second anti-TNF therapy
than patients who did not develop ADA against the first
anti-TNF drug [21,22]. Until now, no data have been
published about the association between immunogeni-
city to the first anti-TNF drug and the clinical response
after switching to a second anti-TNF drug in SpA
patients. In this study, we analysed whether the clinical
response to a second anti-TNF drug is conditioned by
the development of ADA against the first anti-TNF
drug in a group of SpA patients.
Materials and methods
Patients and sera
A total of 42 SpA patients (27 AS, 10 nonradiographic
axial SpA, 2 SpA associated with IBD, 2 psoriatic SpA
and 1 SpA secondary to reactive arthritis) without pre-
vious biological treatment were included. All of these
patients had axial involvement and most of them had
some peripheral articular manifestation as dactylitis,
enthesopathy, monoarthritis and oligoarthritis (28/42
(66.7%) SpA patients: 13 AS, 10 nonradiographic axial
SpA, 2 psoriatic SpA, 2 SpA related to IBD and 1 reac-
tive arthritis. The patients were enrolled at the Depart-
ment of Rheumatology of La Paz University Hospital.
This was an ambispective observational study that was
approved by the La Paz Hospital Ethics Committee, and
all patients provided informed written consent. The ret-
rospective study period covered the years 2005 to 2008,
and the prospective study period covered 2009 to 2011.
All of the AS patients fulfilled the New York revised cri-
teria for AS [23]. The psoriatic arthritis patients fulfilled
the GRAPPA group criteria [24].
All patients received anti-TNF drugs as a first biologi-
cal treatment (infliximab (Ifx), adalimumab (Ada) and
etanercept (Etn)) and later switched to a second anti-
TNF drug (Ifx, Ada, Etn and golimumab (Gol)). The
selection of all anti-TNF drugs was left to the discretion
of the physician, with consideration of patient character-
istics, type of disease, and patient preference. Owing to
the observational design of the study, no specific criteria
for drug withdrawal were required, and the diagnoses of
treatment failure and adverse events were based on the
judgement of the treating physician. Ifx was adminis-
tered intravenously at 5 mg/kg at 0, 2 and 6 weeks and
every 8 weeks thereafter, and the remaining anti-TNF
drugs were administrated subcutaneously (Ada, 40 mg/2
weeks; Etn, 50 mg/week; and Gol, 50 mg/month).
Disease activity was measured by the Ankylosing
Spondylitis Disease Activity Score (ASDAS) [25,26] and
was assessed at baseline and every 6 months. At the
time of inclusion, all patients had evidence of active
spinal disease, as indicated by a mean ASDAS of 3.42 ±
1.01. Clinically important improvement was defined as
change in ASDAS ≥1.1 [26]. Data related to the clinical
activity in the retrospective period were obtained from
our database of patients on biological therapy.
Blood samples were collected a maximum of 24 hours
before biological drug administration for subcutaneous
anti-TNF or just before intravenous infusion for Ifx.
Precise timing was required to compare the results
because the drug levels in the serum can become unde-
tectable over longer time intervals as a result of normal
drug pharmacokinetics rather than the formation of
immunocomplexes with ADA. All sera, including those
of the retrospective period, were stored at -20°C until
the drug and ADA concentrations were measured.
Measurement of drug and anti-drug antibody
concentrations
The serum drug concentrations (Ifx, Ada and Etn) were
determined by sandwich ELISA, as described previously
[27-29]. Serum drug levels were considered positive for
Ifx if >10 ng/ml, for Ada if >5 ng/ml and for Etn if >30
ng/ml.
Serum ADA levels (antibodies to Ifx, antibodies to
Ada and antibodies to Etn) were detected using a two-
site (bridging) ELISA, as previously described [27-29].
The cutoff value for the presence of antibodies to Ifx
was established at 50 AU/ml, for antibodies to Ada at
10 AU/ml and for antibodies to Etn at 50 AU/ml.
To determine the cutoff value of each assay, sera from
150 healthy controls and from 100 RA patients without
anti-TNF treatment (70% positive for rheumatoid factor)
were studied. The mean ± 6 standard deviations was
used to establish cutoff points.
Statistical analysis
The statistical analyses were performed using the Statis-
tical Package for the Social Sciences, version 11.0 (SPSS,
Chicago, IL, USA). Descriptive statistics included the
mean and standard deviation or the median and inter-
quartile range. Differences in baseline characteristics
were assessed using Pearson’s chi-square test and Fish-
er’s exact test for ordinal variables and using the Mann-
Whitney U test for continuous variables. The continu-
ous data were compared between groups using the
Mann-Whitney U test. Statistical significance was calcu-
lated using the log-rank test, and p < 0.05 was consid-
ered significant.
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Results
Patient characteristics
A total of 42 SpA patients were enrolled in this study
with a mean ± standard deviation age of 49.6 ± 10.4
years at the time of inclusion, and 23 (54.8%) were men.
The baseline demographic and clinical characteristics of
the global patient population, categorised according to
future ADA development against the first anti-TNF ther-
apy, are shown in Table 1. No differences in patient char-
acteristics were present at baseline between those who
later developed ADA and those who did not (Table 1).
Immunogenicity in relation to biological therapy
All 42 patients were treated with an anti-TNF drug as
the first biologic therapy (20 with Ifx, 5 with Ada and
17 with Etn) and were switched to a second anti-TNF
treatment (9 Ifx, 19 Ada, 8 Etn and 6 Gol) due to ineffi-
cacy (39 out of 42 patients, 92.8%; 11 of them ADA-
positive) and/or adverse events (8 out of 42 patients,
19%). Of the eight patients who withdrew due to adverse
events, three had been treated with Ifx (all of them with
ADA and clinical inefficacy, having infusion-related
reactions) and five with Etn (two out of five patients
also had clinical inefficacy, all of them having local
injection reaction and/or pruritus).
ADA were detected in 11 (26.2%) patients (7/27
(25.9%) AS, 3/10 (30%) undifferentiated SpA and 1/2
(50%) SpA related to IBD) during treatment with the
first anti-TNF drug and were more frequent in patients
treated with Ifx (9 (81.8%) with Ifx, 2 (18.2%) with Ada,
0 (0%) with Etn, p = 0.006). ADA appeared mainly
within the first year of anti-TNF therapy (mean ± stan-
dard deviation: 12.89 ± 5.92 months), except for five
patients in whom ADA were detected at 18 months (2
patients), 20 months (2 patients) and 28 months (1
patient). At 6 months after switching to the second anti-
TNF drug, ADA were detected in only two patients
treated with Ifx, who had not previously developed anti-
bodies against the first anti-TNF drug. The drug and
ADA concentrations were not evaluated for Gol.
Most patients without ADA (28/31) against the first
anti-TNF drug had clinical inefficacy and detectable
serum drug levels just before the switch to the second
anti-TNF drug (median (interquartile range): 3,008 (680
to 3,076) ng/ml for Ifx, 3,072 (2,048 to 4,096) ng/ml for
Ada, 1,111 (683 to 2,077) ng/ml for Etn), so these
patients were considered as having a primary inefficacy.
Only three patients treated with Etn without detectable
antibodies before switching did not have loss of efficacy
and they were switched due only to adverse events.
Furthermore, all of 11 patients with ADA against the
first anti-TNF treatment had loss of efficacy and unde-
tectable drug levels before switching, so they were classi-
fied as having secondary inefficacy related to
development of immunogenicity.
Clinical response in relation to immunogenicity
At baseline, no differences in disease activity were
observed between patients who did or did not later
develop ADA against the first anti-TNF drug (baseline
ASDAS first anti-TNF: 3.52 ± 1.03 without ADA vs.
3.14 ± 0.95 with ADA, p = 0.399; baseline ASDAS sec-
ond anti-TNF: 3.36 ± 0.94 without ADA vs. 3.09 ± 0.91
with ADA, p = 0.466). Also, there were no differences in
clinical activity at baseline to the first and second anti-
TNF drugs in patients with and without ADA (without
ADA: 3.52 ± 1.03 to the first anti-TNF vs. 3.36 ± 0.94
to the second anti-TNF, p = 0.383; with ADA: 3.14 ±
0.95 to the first anti-TNF vs. 3.09 ± 0.91 to the second
anti-TNF, p = 0.922).
At 6 months after switching, the patients who had
developed ADA against the first anti-TNF drug had
lower disease activity, as measured by the ASDAS (1.62
± 0.93 with ADA vs. 2.79 ± 1.01 without ADA, p =
0.002) (Figure 1), and more patients had inactive disease
(4 out of 11 (36.4%) with ADA vs. 1 out of 31 (3.2%)
without ADA, p = 0.002) (Figure 2). After 6 months of
switching, most patients without ADA against the first
anti-TNF drug were classified as being in a high or very
high disease activity state by the ASDAS (25 out of 31
(80.6%) without ADA vs. 3 out of 11 (27.3%) with ADA,
p = 0.002) (Figure 2).
Table 1 Demographic characteristics of 42
spondyloarthritis patients
Characteristic Total (42
patients)
Without ADA
(31 patients)
With ADA
(11 patients)
p
value
Sex, male 23 (54.8%) 16 (51.6%) 7 (63.6%) 0.726
Age 49.60 ±
10.46
51.26 ± 10.08 44.91 ± 10.53 0.084
HLA-B27-positivea 23/36
(64%)
17/27 (63%) 6/9 (66.7%) 0.841
Disease duration
(years)
12.24 ±
8.23
11.61 ± 8.04 14 ± 8.92 0.416
Baseline ASDAS 3.42 ±
1.01
3.52 ± 1.03 3.14 ± 0.95 0.399
Concomitant
treatment
Methotrexate 9 (21.5%) 8 (25.8%) 1 (9.1%) 0.498
Other
DMARDs
10 (23.8%) 5 (16.1%) 5 (45.4%) 0.115
Methotrexate
+ other
1 (4,7%) 2 (6.4%) 0 (0%) 0.599
DMARDs
Monotherapy 21 (50%) 16 (51.7%) 5 (45.5%) 0.126
Corticosteroid
therapy
15 (35.7%) 9 (29%) 6 (50%)
Data presented as n (%) or mean ± standard deviation. ADA, anti-drug
antibodies; ASDAS, Ankylosing Spondylitis Disease Activity Score; DMARD,
disease-modifying anti-rheumatic drug. an/total number (%).
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At 6 months after switching we observed a greater
clinical improvement, as measured by change in
ASDAS, in patients with ADA as compared with those
without ADA (1.49 ± 1.27 with ADA vs. 0.56 ± 1.01
without ADA, p = 0.014) (Figure 3). A total of 13
patients achieved clinically relevant improvement, and
clinical improvement was more frequent in patients who
had developed ADA (8t out of 11 (72.7%) with ADA vs.
5 out of 31 (16.1%) without ADA, p = 0.001). Three out
of the five patients without ADA who had an important
clinical improvement after switching were treated with
Etn as the first anti-TNF drug and the reason for change
to a second anti-TNF drug was adverse effects.
When a subanalysis is performed taking only the
group of patients with AS (n = 27), we observed that
our results in relation to clinical activity and immuno-
genicity are consistent with those observed analysing all
42 patients. At baseline of the first and second anti-TNF
drugs, no differences were seen in clinical activity
(ASDAS) between patients with and without ADA
(baseline first anti-TNF: 3.61 ± 1.11 without ADA vs.
3.57 ± 0.83 with ADA, p = 0.929; baseline second anti-
TNF: 3.43 ± 0.77 without ADA vs. 2.87 ± 1.01 with
ADA, p = 0.136). However, 6 months after switching
the clinical activity was lower in patients with previous
ADA (2.78 ± 1.05 without ADA vs. 1.38 ± 0.75 with
ADA, p = 0.0.004).
No differences were observed in clinical activity and
clinical improvement between patients treated with a sec-
ond anti-TNF drug with a mAb or fusion protein (ASDAS
after 6 months of switching: 2.47 ± 1.12 with mAb vs. 2.53
± 1.11 with fusion protein, p = 0.908; change in ASDAS
after 6 months of switching: 0.73 ± 1.17 with mAb vs. 1.13
± 1.03 with fusion protein, p = 0.372).
Discussion
In this article we studied the role of immunity against a
first anti-TNF drug in the short-term response to a sec-
ond anti-TNF drug in a group of SpA patients. We
show that patients in whom drug discontinuation was
associated with ADA development achieved a better
clinical response at 6 months after switching than
patients who had not developed ADA.
Figure 1 Association between clinical activity (Ankylosing
Spondylitis Disease Activity Score) and immunogenicity.
Ankylosing Spondylitis Disease Activity Score (ASDAS; mean ±
standard deviation) measured at baseline (first and second anti-TNF
drugs) and at 6 months after switching to a second anti-TNF drug
in patients who did or did not develop anti-drug antibodies (ADA)
against the first anti-TNF drug.
Figure 2 Association between anti-drug antibody status and
clinical activity (Ankylosing Spondylitis Disease Activity Score)
after switching. Clinical activity classified into inactive (light
shading), moderate (medium shading) and high/very high activity
(dark shading), according to Ankylosing Spondylitis Disease Activity
Score criteria, 6 months after switching to a second anti-TNF drug
in patients who had developed anti-drug antibodies (ADA) against
the first anti-TNF drug.
Figure 3 Association between clinical improvement (change in
Ankylosing Spondylitis Disease Activity Score) and
immunogenicity. Change in Ankylosing Spondylitis Disease Activity
Score (delta-ASDAS) measured 6 months after switching in
spondyloarthritis patients who presented or not anti-drug
antibodies (ADA) against the first anti-TNF. Data shown as
interquartile ranges (p75, upper edge; p25, lower edge; p50, midline
of the box).
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Anti-TNF drugs are the only biological therapies avail-
able to treat SpA patients with an inadequate response
to conventional treatment, and their efficacy has been
demonstrated in several randomised placebo-controlled
studies [2-9]. However, a number of patients fail to
respond or experience adverse events necessitating treat-
ment discontinuation [11,17,20,30,31]. Thus, it is crucial
to know what factors predict the treatment response in
SpA patients. Different predictors of a favourable
response to the first anti-TNF drug have been reported
in the literature, including shorter disease duration,
younger age, HLA-B27 positivity, a lower Bath Ankylos-
ing Spondylitis Functional Index score, higher C-reactive
protein levels, a higher Bath Ankylosing Disease Activity
Index score, male sex and the presence of peripheral
arthritis and spinal inflammation on magnetic resonance
imaging [18,32-39]. These data were not analysed in the
present study because we only recruited SpA patients
who had discontinued their first anti-TNF drug.
Only a few prospective studies have reported detailed
information about switching to a second anti-TNF drug
in AS patients [11,40,41]. One recent publication
showed that switching to a second anti-TNF drug could
benefit some AS patients, and up to one-third of
patients achieved a good response [11]. However, dis-
ease activity at 3 months after switching was generally
worse for switchers on their second anti-TNF drug than
for nonswitchers [11]. Similar findings were observed in
another study that included 1,250 AS patients, 326 of
whom had previously received an anti-TNF drug [37].
In this study, anti-TNF-naïve AS patients achieved
greater treatment responses than patients who switched
to a second anti-TNF drug [37].
The immunogenicity of biological therapies has been
shown to influence secondary inefficacy in rheumatic dis-
eases [17,28,42-52]. The frequency of ADA development
in SpA patients varies between different studies (25.5 to
29% for antibodies to Ifx and 31% for antibodies to Ada)
[17,19,20,49-51]. Several publications have described the
relationship between the development of ADA and the
clinical response in SpA patients [17,19,20,52-54]. In pre-
vious work conducted by our group, antibodies to Ifx
were detected in 25.5% of SpA patients treated with Ifx,
and a strong correlation was observed between antibodies
to Ifx development and clinical response as measured by
the ASDAS [49]. de Vries and colleagues observed that
31% of AS patients treated with Ada developed antibodies
to Ada, and most of the patients did not reach an ASAS
response after 6 months of treatment [20]. In this study,
26.2% (11/42) of patients who discontinued the first anti-
TNF drug had detectable ADA, and most had exhibited a
good response to therapy until ADA development. How-
ever, the majority of SpA patients without ADA who
switched to a new anti-TNF drug never demonstrated
clinical improvement, and indeed they typically had a
detectable serum drug concentration. These findings may
suggest that TNF is not the main cytokine instigating dis-
ease activity in these patients or that symptoms in these
patients are not related to the inflammatory activity of
the disease.
Currently, there are only two reports that relate
immunogenicity status to the first anti-TNF drug and its
clinical response after switching to a second anti-TNF
drug in RA patients [21,22]. Bartelds and colleagues
observed that RA patients who had developed antibodies
to Ifx against the first anti-TNF drug had no significant
differences in clinical improvement after switching
(change in Disease Activity Score for 28 joints) when
compared with anti-TNF-naïve patients [21]. Neverthe-
less, switchers without antibodies to Ifx exhibited a sig-
nificantly lower clinical response than naïve RA patients
[21]. Similar findings were reported in a subsequently
published study in RA patients (naïve and switchers)
treated with Etn [22], which demonstrated that naïve
patients and switchers with ADA had a greater clinical
response than did patients who switched without ADA
[22]. To our knowledge, the present work is the first
report in which the influence of immunogenicity against
the first anti-TNF drug has been associated with clinical
activity after switching in SpA patients. As shown above,
clinical improvement was greater in patients who
switched after developing ADA, and 73% of patients
who achieved clinical improvement after switching had
developed ADA to the previous anti-TNF drug.
Our study has several limitations. The number of
patients is relatively small because all patients came from
the same centre, and SpA patients are less likely than RA
patients to discontinue anti-TNF drug [38,41]. However,
our results show differences in treatment outcomes that
are similar to those described after switching anti-TNF
drugs in RA [21,22]. Furthermore, the decision to stop
therapy or to change drugs was not standardised because
it was based on the decision of the responsible rheumatol-
ogist. This may explain why disease activity, although not
significantly different at the baseline of the second anti-
TNF drug, was slightly lower in the group that developed
ADA, because patients are more sensitive to deterioration
once they have previously improved, and the switch is per-
formed at lower levels of disease activity. However, it is
important to highlight that this is the pattern normally
used to determine whether a therapeutic change is
required in clinical practise. Finally, different anti-TNF
drugs were used in the study, both as the first and the sec-
ond anti-TNF therapies, which may have influenced the
results. However, no differences in the effectiveness of the
three most commonly used anti-TNFs have been demon-
strated in clinical practice in AS [55], so it is unlikely that
this would have affected the results.
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Conclusions
Similar to RA, the failure to respond to a first anti-TNF
drug due to the development of ADA predicts a better
clinical response to a second biological treatment in
SpA. The presence of ADA against the first anti-TNF
drug is a determining factor for the response to a sec-
ond anti-TNF drug. The study of the immunogenicity in
biological treatment failure may help predict the
response to a second biological treatment in SpA.
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